Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

RO7895515 clinical trials

Source: EU Clinical Trials Information System (CTIS) — the 2 authorised or ongoing trials that list a product named RO7895515. It is not named in any ClinicalTrials.gov record in our registers. Synced 10 Nov 2026
2EU trials (CTIS)
0With a site in Ireland
1Lead sponsor
1Register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from EU CTIS registry records · Synced · Editorial standards
At a glance

RO7895515 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 3. The sponsor is F. Hoffmann-La Roche AG. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.

Patient leaflets for RO7895515

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

01

RO7895515 in the EU trials register (CTIS)

2 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named RO7895515. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE WEEKLY PETRELINTIDE VS. PLACEBO IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY
2026-526188-39-00 · CTIS ↗ · Nutritional and Metabolic Diseases
 Phase 3 Authorised F. Hoffmann-La Roche AG Denmark, France, Italy
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE WEEKLY PETRELINTIDE VS. PLACEBO IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES
2026-526189-25-00 · CTIS ↗ · Nutritional and Metabolic Diseases
 Phase 3 Authorised F. Hoffmann-La Roche AG Poland
02

Conditions studied with RO7895515

1 condition
Nutritional and Metabolic Diseases2
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
F. Hoffmann-La Roche AG2
04

By country register

RegisterTrialsRecruiting
EU register (CTIS)2—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

05

Questions about RO7895515 trials

How many clinical trials are testing RO7895515?

2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named RO7895515, as of the registry sync on 10 November 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.

Who sponsors RO7895515 clinical trials?

The lead sponsor is F. Hoffmann-La Roche AG. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how RO7895515 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RO7895515 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RO7895515 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.